Aesica Pharmaceuticals
Financials
Estimates*
GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | 15.7m | 20.6m | 23.1m | 26.1m | 15.5m | 11.2m | 5.1m |
% growth | (33 %) | 31 % | 12 % | 13 % | (41 %) | (27 %) | (55 %) |
EBITDA | 3.2m | 3.1m | 1.9m | 2.8m | (1.5m) | (10.8m) | (23.1m) |
% EBITDA margin | 20 % | 15 % | 8 % | 11 % | (10 %) | (96 %) | (454 %) |
Profit | 3.1m | 11.4m | 6.6m | (1.2m) | 7.1m | 1.4m | (24.4m) |
% profit margin | 20 % | 55 % | 29 % | (5 %) | 46 % | 13 % | (479 %) |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Growth Equity VC | ||
$374m Valuation: $374m 17.5x EV/LTM Revenues -65.9x EV/LTM EBITDA | Acquisition | ||
Total Funding | - |
Recent News about Aesica Pharmaceuticals
EditAesica Pharmaceuticals, a part of Recipharm, is a leading global Contract Development and Manufacturing Organization (CDMO) specializing in the pharmaceutical industry. The company offers a wide range of services including drug development, manufacturing, and packaging solutions to pharmaceutical companies worldwide. Aesica serves clients ranging from small biotech firms to large pharmaceutical corporations, operating in a highly competitive and regulated market.
The business model of Aesica revolves around providing end-to-end solutions for the pharmaceutical lifecycle, from initial development through to commercial manufacturing and packaging. This integrated approach allows clients to streamline their supply chains and reduce time-to-market for new drugs. Aesica generates revenue through long-term contracts and project-based engagements, ensuring a steady income stream while fostering strong client relationships.
Aesica's market position is bolstered by its commitment to quality, regulatory compliance, and innovation. The company continuously invests in state-of-the-art facilities and cutting-edge technologies to meet the evolving needs of the pharmaceutical industry. With a global footprint and a diverse portfolio of services, Aesica is well-positioned to capitalize on the growing demand for outsourced pharmaceutical development and manufacturing services.
Keywords: CDMO, pharmaceutical manufacturing, drug development, packaging solutions, biotech, regulatory compliance, innovation, global footprint, supply chain, long-term contracts.